Showing 21-30 of 40 results for "".
- Answered: Your Questions About Employee Management and COVID Risk Mitigationhttps://practicaldermatology.com/news/answered-your-questions-about-employee-management-and-covid-risk-mitigation/2460650/Can I require staff to get a vaccine in order to continue working? In many cases, vaccines can be required, says Josh Alloy, JD, Counsel at Arnold and Porter in Washington, DC, “although there are potential exceptions, and businesses should also consider other ways of incentivizing staff to be vac…
- Beiersdorf Inc. Observes 10 Years of dermMentors Residents of Distinctionhttps://practicaldermatology.com/news/beiersdorf-inc-observes-10-years-of-dermmentors-residents-of-distinction/2460577/As part of the dermMentors™ Resident of Distinction Award™, Beiersdorf Inc. sponsored five top dermatology residents to attend the 16th Annual Coastal Dermatology Symposium, held in a Virtual Format for 2020. The 2020 Residents of Distinction are Shaundra Eichstadt, MD, of Tufts Medical Center; …
- New Allergan Aesthetics and Skinbetter Initiative Aims to Advance Health Equity and Diversity in Aestheticshttps://practicaldermatology.com/news/new-initiative-allergan-aesthetics-and-skinbetter-aims-to-advance-health-equity-and-diversity-in-aesthetics/2460526/Allergan Aesthetics, an AbbVie company, and Skinbetter Science have launched a new long-term, educational initiative—DREAM: Driving Racial Equity in Aesthetic Medicine—to further the principles of racial and ethnic diversity, inclusion, respect and understanding in the fields of dermatology and pla…
- Highlights from Day 3 at DERM2019: Hyperhidrosis, Bug Bites, Sunscreen, and Morehttps://practicaldermatology.com/news/highlights-from-day-3-at-derm2019-hyperhidrosis-bug-bites-sunscreen-and-more/2460101/As the nation observed the 50th anniversary of the Apollo 11 lunar landing, the day the famous quote from astronaut Neil Armstrong was spoken “That’s one small step for a man, one giant leap for mankind," DERM2019 organziers say the shot for the stars with their faculty were not disappointed by the…
- Brooke Shields Takes on New Role as Celebrity Spokesperson for SculpSure Body Contouringhttps://practicaldermatology.com/news/brooke-shields-take-on-new-role-as-celebrity-spokesperson-for-sculpsure-body-contouring/2460005/Actress, model, Broadway star, and author Brooke Shields will serve as national spokesperson for Hologic’s Cynosure's SculpSure body contouring laser treatment. As the face of SculpSure’s new “Be strong. Be sexy. Be confident.” campaign, Ms. Shields will inspire consumers to live confidently in a b…
- Fibrocell to Collaborate with Castle Creek Pharmaceuticals to Develop and Commercialize RDEB Gene Therapyhttps://practicaldermatology.com/news/fibrocell-to-collaborate-with-castle-creek-pharmaceuticals-to-develop-and-commercialize-rdeb-gene-therapy/2460004/Fibrocell Science, Inc. has entered into a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disorder diagn…
- New Acoustic Shockwave Technology May Speed Laser Tattoo Removalhttps://practicaldermatology.com/news/new-acoustic-shockwave-technology-may-speed-laser-tattoo-removal/2457548/Soliton, Inc. is introducing new acoustic shockwave technology for quicker laser tattoo removal. What’s more, the new device also shows potential in aesthetics market for cellulite and fat removal. The patented Rapid Acoustic Pulse (RAP) device uses acoustic shockwaves that accelerated the speed…
- Glenmark Pharmaceuticals Presents New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at IID Meetinghttps://practicaldermatology.com/news/glenmark-pharmaceuticals-presents-new-data-on-gbr-830-an-investigational-anti-ox40-monoclonal-antibody-at-iid-meeting/2457760/Glenmark Pharmaceuticals shared data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD), that were presented at the International Investigative Dermatology Meeting (IID) i…
- Glenmark Pharmaceuticals Reports Positive Phase 2a Data for GBR 830 for Atopic Dermatitishttps://practicaldermatology.com/news/glenmark-pharmaceuticals-reports-positive-phase-2a-data-for-gbr-830-for-atopic-dermatitis/2458102/Glenmark Pharmaceuticals shared positive data from a Phase 2a study of GBR 830, an investigational, anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis (AD). The study evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830, relative to placebo, in …
- Syneron Candela Completes Transaction with Funds Advised by Apax Partners; Becomes a Private Companyhttps://practicaldermatology.com/news/syneron-candela-completes-transaction-with-funds-advised-by-apax-partners-becomes-a-private-company/2458121/Syneron Medical Ltd. announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400 million. The transaction was announced on April 3, 2017 and received approval from Syneron Cande…